The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL), a joint Liberia-United States research partnership, has launched a Phase I clinical study to evaluate a candidate Lassa fever vaccine in adults of good health in Liberia. Lassa fever is a viral disease found in rats living in West Africa. The World Health Organization (WHO) estimates that 80% of infected individuals with the Lassa virus have no symptoms. PREVAIL physician Dr. Mark Kieh will lead the Lassa fever vaccine study at the Redemption Hospital which will last for 14 months. “The prospect of developing a vaccine that will prevent Lassa fever is a great step forward,” says Dr. Kieh.

Source: Daily Observer September 01, 2022 04:55 UTC